Aptar Pharma, a U.S.-based company, announced that its Mezzo+ CS (China Support) Airless dispensing solution has received market approval in China. This innovative system is designed for dermal drug delivery and will be utilized for Sinomune Pharmaceutical’s metronidazole gel, which has been approved by the National Medical Products Administration (NMPA) for the treatment of papulopustular rosacea—an inflammatory skin condition characterized by pustules, predominantly affecting the central face and often resulting in acne breakouts.
Aptar’s Airless+ technology boasts several advantages, including reliable dispensing from any angle, precise dosing, and reduced product wastage, enhancing the overall user experience.- Flcube.com
